STOCK TITAN

Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will announce its 2021 first quarter financial results on May 4, 2021, after market close. A live audio webcast will follow at 4:30 p.m. ET for discussion of the results and business updates. Interested parties can access the webcast via the company's website. Jazz Pharmaceuticals focuses on developing medicines for serious diseases, particularly in neuroscience and oncology, serving patients in over 90 countries.

Positive
  • Focus on developing life-changing medicines for serious diseases.
  • Diverse portfolio of marketed medicines and novel products.
Negative
  • None.

DUBLIN, April 19, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after the close of the financial markets. Company management will host a live audio webcast at 4:30 p.m. ET/9:30 p.m. IST to discuss first quarter 2021 financial results and provide a business and financial update.  

Audio webcast/conference call:
U.S. Dial-In Number: +1 855 353 7924
International Dial-In Number: +1 503 343 6056
Passcode: 8765706

A replay of the conference call will be available through May 11, 2021:

Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number: +1 404 537 3406
Passcode: 8765706

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. A replay of the webcast will be archived on the website for at least one week.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

Jazz Pharmaceuticals Contacts:


Investors: 
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
U.S. +1 561 306 4035

Media:
Jacqueline Kirby
Vice President, Corporate Affairs & Government Relations
Ireland +353 1 697 2141
U.S. +1 215 867 4910

 

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2021-first-quarter-financial-results-on-may-4-2021-301270880.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals report its Q1 financial results?

Jazz Pharmaceuticals will report its 2021 first quarter financial results on May 4, 2021.

What time is the Jazz Pharmaceuticals financial results webcast?

The webcast will be held at 4:30 p.m. ET on May 4, 2021.

How can I access the Jazz Pharmaceuticals financial results webcast?

The webcast can be accessed through the Investors section of the Jazz Pharmaceuticals website.

What are the key therapeutic areas for Jazz Pharmaceuticals?

Jazz Pharmaceuticals focuses on neuroscience, including sleep medicine and movement disorders, and oncology.

Jazz Pharmaceuticals, Inc.

NASDAQ:JAZZ

JAZZ Rankings

JAZZ Latest News

JAZZ Stock Data

7.45B
58.63M
2.94%
98.71%
6.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DUBLIN